Coloplast (COLO) AGM 2025 summary

Opening remarks and agenda

• Board and management introduced, with formal appointment of AGM chairman and confirmation of lawful meeting convening.

• Meeting agenda included reports on company activities, annual report approval, profit allocation, remuneration, proposals, board and auditor elections, and other business.

Financial performance review

• Organic revenue growth reached 7%, with DKK 27.9 billion in revenue and a 28% profit margin before special items.

• Net profit for the year was DKK 3,636m, with free cash flow at DKK 5,394m.

• Return on invested capital after tax and before special items was 15%.

• Share price declined from 875 DKK (Sep 2024) to 543 DKK (Dec 2025).

• Outlook for 2025-2026: organic growth and EBIT growth both expected at around 7%, with ROIC at 16%.

Board and executive committee updates

• Leadership transition underway: interim CEO Lars Rasmussen in place, with search for new CEO ongoing.

• Board members Annette Brüls, Carsten Hellmann, Jette Nygaard-Andersen, Marianne Wiinholt, and Niels Peter Louis-Hansen proposed for re-election; Niels B. Christiansen proposed as new member and expected future chairman.

• New executive structure: two business units (Chronic Care and Acute Care) established to align with strategy.